Comparison of M-TAPA and External Oblique Intercostal Block for Intraoperative Opioid Consumption in Laparoscopic Cholecystectomy (MTAPA-EOI)
Comparison of M-TAPA and External Oblique Intercostal Plane Block on Intraoperative Analgesia and Opioid Consumption Guided by Skin Conductance Algesimeter in Laparoscopic Cholecystectomy
This prospective observational study is designed to evaluate the effects of modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal (EOI) plane block on intraoperative analgesia and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. Abdominal wall blocks are widely used to improve perioperative analgesia; however, their impact on intraoperative opioid requirements when guided by objective nociception monitoring remains unclear.
All patients will receive standardized general anesthesia. Intraoperative analgesia will be guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic nervous system activity by measuring fluctuations in skin conductance. The SCA parameter "peaks per second (PPS)" will be used to assess nociceptive responses. Remifentanil infusion will be titrated according to SCA values to maintain adequate analgesia. Dose adjustments will be performed at predefined intervals, and changes will be considered valid only if sustained for a minimum duration.
Patients will receive either M-TAPA or EOI block as part of routine clinical practice. The choice of block will not be influenced by the investigators, in accordance with the observational design of the study. Data will be collected prospectively during the intraoperative period and postoperative follow-up.
The primary outcome of the study is the time-weighted average intraoperative remifentanil infusion rate (µg/kg/min). Secondary outcomes include total intraoperative remifentanil consumption (µg/kg), intraoperative hemodynamic parameters (heart rate and mean arterial pressure), frequency of deviations in SCA values from the target range, postoperative pain scores assessed using a numeric rating scale (NRS), time to first analgesic requirement, and total rescue analgesic consumption.
Perioperative analgesia will be standardized. All patients will receive intravenous dexketoprofen toward the end of surgery as part of routine clinical practice. Rescue analgesia will be provided with intravenous dexketoprofen when clinically indicated. Additional outcomes include postoperative nausea and vomiting and perioperative complications.
This study aims to provide objective data on the opioid-sparing effects of different abdominal wall block techniques when intraoperative analgesia is guided by nociception monitoring. The findings may contribute to optimizing analgesic strategies and improving perioperative pain management in laparoscopic surgery.
Descripción general del estudio
Estado
Descripción detallada
This prospective observational study evaluates intraoperative opioid requirements under nociception-guided analgesia in patients undergoing elective laparoscopic cholecystectomy. Analgesic management is guided by the Skin Conductance Algesimeter (SCA), which reflects sympathetic activation through fluctuations in palmar skin conductance. The SCA-derived parameter "peaks per second (PPS)" is used as a real-time surrogate of nociceptive activity.
General anesthesia is administered according to institutional standards. Remifentanil is delivered via continuous infusion and titrated in response to SCA values to maintain a predefined nociception-analgesia balance. Dose adjustments are performed in stepwise increments, with changes considered valid only if sustained over a defined period. Hemodynamic variables are monitored concurrently but are not the primary determinants of opioid titration.
Abdominal wall analgesia is provided using either modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) or external oblique intercostal (EOI) plane block, both applied as part of routine clinical practice. In line with the observational design, no allocation or intervention is performed by the investigators, and block selection is based on standard clinical decision-making.
Intraoperative data are recorded at fixed time intervals, including heart rate, mean arterial pressure, SCA-derived PPS values, and remifentanil infusion rates. The primary endpoint is the time-weighted average remifentanil infusion rate (µg/kg/min), reflecting overall intraoperative opioid requirement normalized to surgical duration. Secondary analyses include total opioid exposure, frequency and magnitude of deviations from target nociception ranges, and perioperative analgesic requirements.
Intravenous dexketoprofen is administered toward the end of surgery as part of routine clinical care. Postoperative outcomes include pain intensity assessed using a numeric rating scale (NRS), time to first analgesic request, and additional analgesic consumption. Postoperative nausea, vomiting, and perioperative adverse events are also recorded.
This study aims to characterize the relationship between nociception-guided opioid titration and regional anesthesia techniques, and to determine the relative contribution of abdominal wall blocks to intraoperative opioid sparing under objective monitoring conditions.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: İsmet Uluhan, MD
- Número de teléfono: +905077128389
- Correo electrónico: ismtptlk@gmail.com
Ubicaciones de estudio
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turquía (Türkiye)
- Reclutamiento
- Ankara Etlik City Hospital
-
Contacto:
- İsmet Uluhan, MF
- Número de teléfono: +905077128389
- Correo electrónico: ismetuluhan@outlook.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients aged 18-80 years
- ASA physical status I-III
- Scheduled for elective laparoscopic cholecystectomy under general anesthesia
- Ability to provide written informed consent
Exclusion Criteria:
- Patient refusal
- Known allergy to local anesthetics
- Chronic opioid use or opioid dependence
- Neurological or psychiatric disorders affecting pain perception
- Use of medications affecting autonomic nervous system activity, such as beta-blockers
- Infection at the injection site
- Coagulopathy or anticoagulant therapy
- Pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
M-TAPA Group
Patients receiving ePatients receiving modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) for intraoperative analgesia during laparoscopic cholecystectomy.ternal
oblique intercostal plane block (EOI) for analgesia
|
|
EOI Group
Patients receiving external oblique intercostal plane (EOI) block for intraoperative analgesia during laparoscopic cholecystectomy.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time-Weighted Mean Intraoperative Remifentanil Infusion Rate
Periodo de tiempo: Intraoperative period (from induction to end of surgery)
|
The time-weighted mean intraoperative remifentanil infusion rate will be calculated throughout the surgical period and expressed as micrograms per kilogram per minute (µg/kg/min) based on continuous infusion data.
|
Intraoperative period (from induction to end of surgery)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative Pain Scores Assessed by Numeric Rating Scale
Periodo de tiempo: 0, 2, 4, 6, 12, and 24 hours postoperatively
|
Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate worse pain.
Assessments will be performed at rest and during movement.
|
0, 2, 4, 6, 12, and 24 hours postoperatively
|
|
Time to First Analgesic Requirement
Periodo de tiempo: Within 24 hours postoperatively
|
Time to First Analgesic Requirement
|
Within 24 hours postoperatively
|
|
Rescue Analgesic Consumption
Periodo de tiempo: First 24 hours postoperatively
|
Total amount of rescue analgesic (dexketoprofen) administered within the first 24 hours postoperatively.
|
First 24 hours postoperatively
|
|
Mean Arterial Pressure
Periodo de tiempo: Intraoperative period
|
Mean arterial pressure (MAP), expressed in mmHg, will be recorded intraoperatively and compared with baseline values.
|
Intraoperative period
|
|
Heart Rate
Periodo de tiempo: Intraoperative period
|
Heart rate, expressed as beats per minute, will be recorded intraoperatively and compared with baseline values.
|
Intraoperative period
|
|
Skin Conductance Algesimeter(SCA)
Periodo de tiempo: Intraoperative period
|
Skin Conductance Algesimeter (SCA) peaks per second (PPS) values recorded intraoperatively to assess nociceptive responses.
|
Intraoperative period
|
|
Postoperative Nausea and Vomiting (PONV)
Periodo de tiempo: First 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting within the first 24 hours after surgery.
|
First 24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Tulgar S, Selvi O, Thomas DT, Deveci U, Ozer Z. Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) provides effective analgesia in abdominal surgery and is a choice for opioid sparing anesthesia. J Clin Anesth. 2019 Aug;55:109. doi: 10.1016/j.jclinane.2019.01.003. Epub 2019 Jan 9. No abstract available.
- Elsharkawy H, Kolli S, Soliman LM, Seif J, Drake RL, Mariano ER, El-Boghdadly K. The External Oblique Intercostal Block: Anatomic Evaluation and Case Series. Pain Med. 2021 Nov 26;22(11):2436-2442. doi: 10.1093/pm/pnab296.
- Norbeck DW, Lindgren S, Wolf A, Jildenstal P. Reliability of nociceptive monitors vs. standard practice during general anesthesia: a prospective observational study. BMC Anesthesiol. 2025 Jan 31;25(1):51. doi: 10.1186/s12871-025-02923-4.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- AEŞH-EK-2026-019
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .